(Q35728779)

9 August 2017

1 reference

title

Venous thromboembolism and malignancy. (English)

1 reference

9 August 2017

main subject

venous thromboembolism

1 reference

Shuwei Gao

1

1 reference

9 August 2017

Carmen Escalante

series ordinal

2

1 reference

9 August 2017

publication date

1 April 2004

1 reference

Expert Review of Anticancer Therapy

9 August 2017

published in

1 reference

9 August 2017

volume

4

1 reference

9 August 2017

issue

2

1 reference

9 August 2017

page(s)

303-320

1 reference

Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.303

The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.303

Venous thrombosis in cancer patients: insights from the FRONTLINE survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.303

Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.303

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.303

A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.303

First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.303

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.303

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.303

Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.303

Expression of tissue factor correlates with grade of malignancy in human glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.303

Clinical validity of a negative venogram in patients with clinically suspected venous thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.303

Impedance plethysmography: the relationship between venous filling and sensitivity and specificity for proximal vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.303

Decline of proteins C and S and factors II, VII, IX and X during the initiation of warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.303

Increased warfarin doses and decreased international normalized ratio response after nationwide generic switching

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.303

Evaluation of the clinical and economic impact of a brand name-to-generic warfarin sodium conversion program

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.303

A randomized, crossover comparison of warfarin products in the treatment of chronic atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.303

Substitution of generic warfarin for Coumadin in an HMO setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.303

Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.303

A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.303

Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.303

Development and in vivo evaluation of an oral delivery system for low molecular weight heparin based on thiolated polycarbophil

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.303

Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.303

Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.303

Antimetastatic effect of tinzaparin, a low-molecular-weight heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.303

21 January 2018

Identifiers

DOI

10.1586/14737140.4.2.303

1 reference

release_b27hdnu4qzep7lkb7upda76kqy

9 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/b27hdnu4qzep7lkb7upda76kqy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference